Biosimilars Market Research Reports & Industry Analysis

Page 2 of 4
Biosimilars Real World Evidence: Proving the point US$ 2,245.00

... prices addressed. Real World Data (RWD) and Real World Evidence (RWE) play a key role in building stakeholder confidence and establishing market presence. In Biosimilars Real World Evidence: Proving the point ...

Jul, 2017
Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update US$ 525.00

Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update The Competitive Intelligence Report „Anti-VEGF & Anti-VEGF-R Biosimilars and Biosuperiors of Avastin ...

Nov, 2017 58 pages
The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis US$ 4,000.00

... with systemic agents. Driven by improved efficacy, the first group of anti TNF treatments led by Enbrel, Humira and Remicade made strong penetration into the psoriasis market. However the emergence of the IL-17 inhibitor class ...

Oct, 2017 104 pages
Japan Biosimilars – A start of Authorized Biosimilar Era? Biosimilar/BioPharma CMO opportunities – JP Conglomerates – A definite role to play for Global Market! US$ 4,000.00

... ~4000) and early entry of the player are critical factors to decide biosimilar penetration and market share dynamics of Japan Biosimilar Market. While ... in next few years for Japan biosimilar players. In this report, we attempt to evaluate key upcoming opportunity for Japan BS market, its competitive landscape, ...

Aug, 2017 128 pages
Biosimilars Market in India 2017 US$ 950.00

... Netscribes’ latest market research report titled Biosimilars Market in India 2017, describes the current and forecasted dynamics of the biosimilars market in India. The increasing ... has resulted in the growth of this industry in India. Biosimilars are typically marketed at prices that are 25% to 40% below the ...

Apr, 2017 43 pages
The Future of Biosimilars in Europe: Mapping critical uncertainties and the impact of future events US$ 2,245.00

... be involved in decisions about biosimilars? Will biosimilar oncology mAbs see widespread uptake? What should developers target next? For biosimilars to thrive, payers must ... on clinical and patient biosimilar experience Content Highlights Biosimilars in Europe: current status, key developments Key insights Overview The European biosimilars market continues ...

Jun, 2017
Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through Risk Management and Quality by Design US$ 2,995.00

... Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through Risk Management and Quality by Design' provides an in-depth assessment of the current trends in the global biosimilars market, with a particular focus on manufacturing complexities ...

Mar, 2017 117 pages
Global Biosimilar Drug Market Analysis & Forecast Report 2017-2022 US$ 2,600.00

The Global Biosimilar Drug Market Analysis & Forecast Report 2017-2022 is a professional and in-depth study on the current state of the Biosimilar Drug Market. The report analysis the global market of Biosimilar Drug by main manufactures and geographic regions. The report includes Biosimilar Drug definitions, classifications, applications and ...

Feb, 2017 105 pages
Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022 US$ 1,500.00

... Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market ...

Feb, 2017 120 pages
Global Biosimilar Market by Classes (Insulin, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte- Colony Stimulating Factor (G-CSF), Monoclonal Antibody (mAb) and Interferon... US$ 1,200.00

... dynamics in the much nascent US biosimilars market is about to change with long-lasting price competition. The report “Global Biosimilar Market by Classes (Insulin, Erythropoietin (EPO), Human Growth ...

Jan, 2017 112 pages
2017-2022 Global Top Countries Biologics and Biosimilars Market Report US$ 4,960.00

... and is sent in 48 hours after order is placed. This report studies Biologics and Biosimilars in Global market, especially in United States, Canada, ... by Countries, this report splits Global into several key Countries, with sales, revenue, market share of top 5 players in these Countries, from 2012 to 2017 ( ...

Dec, 2016 126 pages
2017 Top 5 Biologics and Biosimilars Manufacturers in North America, Europe, Asia-Pacific, South America, Middle East and Africa US$ 4,960.00

... and is sent in 48 hours after order is placed. This report studies Biologics and Biosimilars in Global market, especially in North America, Europe, Asia ... , revenue, market share of top 5 players in these regions, from 2012 to 2017 (forecast), like North America (United States, Canada and Mexico ... , this report focuses on sales, market share and growth rate of Biologics and Biosimilars in each application, can be divided into Tumor Diabetes ...

Dec, 2016 126 pages
2016 Global Biosimilars Market Status, 2011-2022 Market Historical and Forecasts, Professional Market Research Report US$ 2,800.00

... Version Biosimilars Market Research Report is a deep market research report in this market. This report focused on global and regional market, major manufacturers, as well as the segment market ... 2. Then the global and regional market is analyzed. In these chapters, this report analyzed major market data like capacity, production, capacity utilization ...

Dec, 2016 134 pages
Global Biosimilar Market: Size, Trends & Forecasts (2016-2020) US$ 800.00

... “Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)”, provides an analysis of global biosimilar market in terms of value. The report also provides a brief analysis of the global biologics market by value and market share ... current and future trends. Sandoz, Amgen, Celltrion and Pfizer are some of the key players operating in the global biosimilar market whose company profiling ...

Nov, 2016 58 pages
Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update US$ 1,393.00

... about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar ... , pavilizumab, tocilizumab, and ustekinumab. Download sample pages of Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update Competitor projects are listed in a tabular format providing information ...

May, 2016 462 pages
Global and Chinese Biosimilars Industry, 2016 Market Research Report US$ 2,800.00

... 'Global and Chinese Biosimilars Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Biosimilars industry with a focus on the Chinese market ... a new project of Biosimilars Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2011-2021 global and Chinese Biosimilars industry covering all important ...

Nov, 2016 150 pages
Remicade (Infliximab) Biosimilar Clinical Trial Insight US$ 1,200.00

... location. “Remicade (Infliximab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 17 biosimilar version of Remicade drug in clinical pipeline. Currently there are 2 biosimilars in Phase-III trials and are ...

Oct, 2016 50 pages
Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight US$ 1,000.00

... on the location. “Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Lantus drug in clinical pipeline. Currently 5 biosimilar version of Lantus are commercially ...

Oct, 2016 35 pages
Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight US$ 1,500.00

... Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Herceptin drug in clinical pipeline. Currently there are 4 biosimilars in Phase-III trials ...

Oct, 2016 85 pages
Humira Biosimilars Clinical Trial Insight US$ 1,500.00

... Humira Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 33 biosimilars version of Humira drug in clinical pipeline. More than 10 of these biosimilars are in Phase-III trials ...

Oct, 2016 80 pages
Enbrel Biosimilars Clinical Trial & Opportunity Insight US$ 1,500.00

... Enbrel Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 36 biosimilar version of Enbrel drug in clinical pipeline. More than 5 of these biosimilars are in Phase-III trials ...

Oct, 2016 70 pages
Global Biosimilars Market and Forecast (By Product Type, Applications, Country Wise and Companies) to 2021 and Biosimilars Approved and Pipeline Analysis US$ 1,350.00

... 1. Global Biosimilars Market and Forecast - By Product Type 2. Global Biosimilars Market and Forecast - By Applications 3. Global Biosimilars Market and Forecast - By Country Wise 4. Global Biosimilars Company - Profile, Revenue, Approved and Pipeline Biosimilars Analysis 5. Country with Biosimilar Guideline ...

Oct, 2016 177 pages
EPO Biosimilars - The Future of Erythropoietin Market US$ 600.00

... . However, the biosimilar versions of these drugs are expected to witness precipitous growth owing to their low cost. As per RNCOS report “EPO Biosimilars - The ... segmented into biologic and biosimilar erythropoietin markets. The report also highlights the various biologic and biosimilar erythropoietin drugs currently available ...

Aug, 2016 45 pages
Analyzing the Global Biosimilars Industry 2016 US$ 1,100.00

... biosimilars is growing. Aruvian Research analyzes the global biosimilars industry in its research report Analyzing the Global Biosimilars Industry 2016. In this research report, we analyze what biosimilars ... -wise analysis of the biosimilar industry. Biosimilar markets are analyzed in Australia, BRIC nations ...

Jul, 2016 285 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update US$ 560.00

Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update Humira, Enbrel and Remicade ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

May, 2016 124 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update US$ 335.00

Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-Her2 Antibodies 2016 updates the ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

May, 2016 84 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update US$ 280.00

Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update This Competitive Intelligence report about Biosimilar and Biosuperior Anti-EGF-R Antibodies updates the competitive ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

May, 2016 56 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update US$ 335.00

Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-CD20 Antibodies 2016 updates the ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

May, 2016 74 pages
Biosimilars in Oncology: Update Bulletin [Feb 2016] US$ 995.00

... on the latest events that have the potential to shape the oncology biosimilars market. Topics covered include opinions about data from Sandoz ... drive down prices to unsustainable levels and cause the biosimilars market in the US to fail? Update Bulletins include expert insight and analysis based on FirstWord ...

Feb, 2016
Competitor Analysis: PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors US$ 220.00

Competitor Analysis: PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors This Competitive Intelligence report titled PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors“ provides a competitor evaluation in the field of protein- and peptide-based agonists of the parathyroid hormone (PTH) receptor ...

Feb, 2016 32 pages
Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update US$ 440.00

Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update The Competitive Intelligence Report Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update“ provides a competitor evaluation in the field ...

Feb, 2016 46 pages
Biosimilars in Oncology: KOL Insight US$ 7,900.00

... to accept biosimilars of proven targeted treatments. So what do pharma companies need to do to increase confidence and ensure uptake of biosimilars in this toughest of markets? Biosimilars in Oncology: KOL Insight spells out the concerns about equivalence, evidence and endpoints with insights into the current ...

Jan, 2016
Biosimilars: Regulatory Outlook US$ 2,100.00

... significant regulatory progress has been made in recent years, clarity is distinctly lacking on certain issues, such as interchangeability and naming.  FirstWord’s Biosimilars: Regulatory Outlook provides insight and opinion on why. This 64 page report gives in-depth and candid views on what eight industry and biosimilar experts ...

Nov, 2015
US Biosimilars Market Opportunity & Clinical Pipeline Analysis US$ 2,400.00

... Biosimilars Market Impact of Biosimilars in US Market Impact of Reimbursement Policies on US Biosimilars Market Zarxio: First Approved Biosimilar in US US Biosimilar Clinical Pipeline By Company, Indication & Phase US Biosimilar Clinical Pipeline: 104 Biosimilars Marketed Biosimilars: 1 Biosimilar ...

Feb, 2016 330 pages
The 2019-2024 World Outlook for Biosimilars US$ 995.00

This study covers the world outlook for biosimilars across more than 190 countries. For each year reported, ... . This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product ...

Jan, 2018 268 pages
Japan Biosimilar- Active Players In Quest of a Specialty & Niche BS space US$ 4,000.00

... , Filgrastim/Pegfilgrastim/ Insulin/Lantus apart from other key complex Mab Biosimilar opportunities and list out niche opportunities in biosimilar space in Japan. It details all major consolidation activities ...

Jan, 2016 101 pages
Global Biosimilars Sales 2015 Market Research Report US$ 4,000.00

The Global Biosimilars Sales 2015 Market Research Report is a professional and in-depth study on the current state of the Biosimilars market. The report provides a basic overview of the Biosimilars industry ... the global Biosimilars market size (volume and value), and the sales segment market is also discussed by product type, application and region. The major Biosimilars market (including ...

Dec, 2015 162 pages
Europe Biosimilars Market Opportunity Outlook 2020 US$ 2,400.00

... European biosimilars market. “Europe Biosimilars Market Opportunity Outlook 2020” Report Highlight: Europe Biosimilars Market Outlook Europe Biosimilars Market Trend Analysis by Country Introduction of Biosimilars in European Market by Segment Clinical & Non Clinical Guidelines Europe Biosimilar ...

Nov, 2015 310 pages
Analysis of USFDA's Approval of Biosimilars Case in Focus: Zarxio (Biosimilar of Amgens Neupogen) US$ 1,000.00

... Regulations around approval biosimilars in the US An overview of global biosimilar market Case study on the US approval of Zarxio (Biosimilar of Amgen’s ... Business Portfolio Planning Strategic/Business Analysis Business Development Licensing Technical Analysis Portfolio Management/Planning Project Management ...

Sep, 2015
Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis US$ 460.00

Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis The Competitive Intelligence report Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis describes product ... G-CSF products represent an attractive market size for biosimilar proteins in regulated markets. Biosimilar filgrastim products have already been introduced into the the ...

Jul, 2015 76 pages
Global Biosimilars Industry 2015 Market Research Report US$ 2,850.00

2015 Global Biosimilars Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Biosimilars industry, focusing on the main regions ... with: 1.) basic information; 2.) the Asia Biosimilars industry; 3.) the North American Biosimilars industry; 4.) the European Biosimilars industry; 5.) market entry and investment feasibility; and ...

Jul, 2015 170 pages
Global & USA BioSimilar Market Analysis to 2021; BioBetters, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte Colony-Stimulating Factor (G-CSF), Anti-Tumor Necrosis Factor... US$ 3,400.00

... , through 2021. Global market for biologics by drug class, through 2021. Global market for biosimilars by region, through 2021. Global market for biosimilars by indication, through 2021. Global market for biosimilars by drug ...

Aug, 2015 271 pages
The Future of Biosimilars 2016 US$ 2,195.00

... Understand the Forces Shaping the Biosimilars Market Commercialisation: Differentiation may be the key success factor for biosimilars. Discover the strategies manufacturers ... biosimilars in Europe shaped attitudes toward switching both treatment-naïve and established patients to biosimilars? Getting crowded: How will the market handle multiple biosimilars ...

Jul, 2016
Physician Views: Will Patient Switching Studies Support Biosimilar Adoption? US$ 695.00

... market will at some point provide a secondary benchmark for biosimilar developers, physicians, patients and payers, when data from a much anticipated 500-patient switching study ... in the EU5 the following questions this week… Has your view towards current/future usage of biosimilar TNF inhibitors become more ...

Jun, 2015
Latest Chinese Guidance for Development, Evaluation, License Approval of Biosimilars US$ 750.00

... latest Chinese guidance for development, evaluation, license approval of biosimilars, Latest Chinese Guidance for Development, Evaluation, License Approval of Biosimilars provided a comprehensive and thorough knowledge of the latest Chinese guidance for development, evaluation, license approval of biosimilars ...

May, 2015 48 pages
Evolution of Technologies for Therapeutic Antibodies-From mAbs to Biosimilars US$ 1,999.00

The report provides in-depth information on technologicial platforms being developed for monoclonal antibodies and how they have been improvised for biosimilar development. Also various issues pertaining to manufacturing of biosimilars have been highlighted with possible solutions to to address the hurdles.

Jan, 2015 64 pages
Physician Views: Oncologists React to Approval of Zarxio – the First US Biosimilar US$ 695.00

... for. FirstWord polled US-based oncologists on this issue, among others, following the ODAC meeting in January (see Physician Views Poll Results: Positive FDA sentiment for biosimilar Neupogen shared by oncologists). While Zarxio is a trailblazer in the ...

Mar, 2015
Physician Views: CMS Guidance on Biosimilar Reimbursement – What Do Oncologists and Rheumatologists Think? US$ 695.00

... physician sentiment to the CMS guidance. In our first poll, focused on Part B reimbursement, we are asking oncologists… How effective they expect the CMS reimbursement guidance to be in incentivising physicians ... of 'de-facto' interchangeability via CMS guidance Their view on interchangeability status for ...

Apr, 2015
Biosimilars: US Payer Perspectives (2018) US$ 2,495.00

... 2018). You won't find entrenched perceptions, old data and out-of-date opinions. Instead, Biosimilars: US Payer Perspectives ... Example insight included in Biosimilars: US Payer Perspectives Payers have devised strategies to encourage the adoption of biosimilars. Currently, payers require prior authorisations, ...

Apr, 2018
Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors US$ 1,500.00

Competitor Analysis: The rapeutic Antibodies 2015: Biosimilars & Biosuperiors This Competitive Intelligence Report about The rapeutic Antibodies 2015: Biosimilars & Biosuperiors provides a competitor ...

Apr, 2015 414 pages
1 2 3 4 >
Skip to top